Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Lymphocytic Leukemia: early-phase trial registry

1 of 5 indexed Lymphocytic Leukemia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Lymphocytic Leukemia: 5 US clinical trials tracked, 1 recruiting.

Lymphocytic Leukemia is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 2 of these trials.

Enrollment posture brief

Registry condition lymphocytic-leukemia

OPEN 1 | RECR 20% | LATE 0 | EARLY 5 | RANK #3391 | SPON 2

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Lymphocytic Leukemia (this)20%
Open-enrollment share among volume-matched conditions near Lymphocytic Leukemia

Lymphocytic Leukemia lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lymphocytic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lymphocytic Leukemia is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Lymphocytic Leukemia research.

    H. Lee Moffitt Cancer Center and Research Institute accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Lymphocytic Leukemia trials plan to enrol fewer than 100 people.

    Median target enrolment is 28 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.

  4. Lymphocytic Leukemia research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 21

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1

Named interventions

Most-linked intervention names on Lymphocytic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

BMS-986345 Drug
1 trials
Stem cell transplantation Procedure
1 trials
alemtuzumab Drug
1 trials
everolimus Drug
1 trials
NeoVax Drug
1 trials
Duvelisib Drug
1 trials
Lenalidomide Drug
1 trials
Rituximab Drug
1 trials

US sites by state

Facility locations filed on Lymphocytic Leukemia trials. A trial with sites in several states counts in each.

Florida 2 trials
Minnesota 1 trials
Maryland 1 trials
Massachusetts 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lymphocytic Leukemia page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphocytic Leukemia condition card totals 5 registered trials; most-linked intervention BMS-986345; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.